
    
      This study is designed to provide evidence of efficacy of cefiderocol in the treatment of
      serious infections in adult patients with either hospital-acquired pneumonia (HAP),
      ventilator-associated pneumonia (VAP), healthcare-associated pneumonia (HCAP), complicated
      urinary tract infection (cUTI), or bloodstream infections (BSI)/sepsis caused by
      carbapenem-resistant Gram-negative pathogens.
    
  